Cost (€) per QALY gained with etanercept plus methotrexate compared with methotrexate alone, sensitivity analyses, 2004
| Base case | Incremental cost (€) | Incremental effect | Cost per QALY gained (v MTX) | |
|---|---|---|---|---|
| 1 euro = 9.20 Swedish kronor. | ||||
| 2 Year treatment, extrapolation to 10 years | ||||
| Direct costs only | 20056 | 0.38 | 52649 | |
| Annual HAQ progression 0 | 14533 | 0.37 | 38726 | |
| Annual HAQ progression 0.06 | 14094 | 0.38 | 36691 | |
| Annual HAQ progression 0.09 | 14130 | 0.38 | 36779 | |
| Costs for patients with high disease activity 20% higher | 13566 | 0.38 | 35700 | |
| Utility difference between the treatment groups reduced by 50% | 14221 | 0.34 | 41667 | |
| No effect of RA on mortality | 13886 | 0.38 | 36655 | |
| Median European price for etanercept | 9719 | 0.38 | 25514 | |
| Starting age 65 years | 20194 | 0.38 | 35700 | |
| Discounting 0% | 13733 | 0.41 | 33176 | |
| Discounting 5% | 14458 | 0.36 | 29947 | |
| 10 Year treatment | ||||
| Higher dropout after trial (double the risk) | 32711 | 0.79 | 41185 | |